NCT00002080已完成不适用
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study
Pharmacia2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 2
研究概览
简要总结
Primary: To provide rifabutin to HIV positive patients in an attempt to prevent or delay Mycobacterium avium Complex (MAC) infection by a daily dose of rifabutin.
Secondary: To further characterize the safety of rifabutin monotherapy in preventing or delaying MAC bacteremia in HIV positive patients with CD4 counts = or < 200.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Any medication with the exception of other investigational drugs not available under a treatment IND, expanded access, or parallel track program.
- •Patients must have:
- •Confirmed HIV infection.
- •CD4 cell counts <= 200 cells/mm
- •No evidence of disseminated MAC disease.
- •Informed consent of parent or guardian if 12 to < 18 years of age.
- •Pregnant females may be eligible. There are no studies of the safety or efficacy of rifabutin in pregnant women. Rifabutin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In addition, a risk/benefit decision should consider the likelihood of a woman's developing MAC if she does not receive prophylaxis. The risk of developing MAC rises substantially for women with CD4 counts less than 100, although it can also develop in women with higher CD4 counts. Women of reproductive potential who are not pregnant must use contraception. They are encouraged to use means other than oral contraceptives.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms and conditions are excluded:
- •Known hypersensitivity to rifabutin, rifampin, or other rifamycins.
- •Current infection due to MAC or other mycobacterial disease, or complaints consistent with tuberculosis.
- •Concurrent Medication:
- •Other investigational drugs with the exception of those available under a treatment IND, expanded access, or parallel track program. (Licensed products prescribed for unlabeled indications are not considered investigational.)
- •Patients with the following prior conditions are excluded:
- •Prior infection due to MAC or other mycobacterial disease or complaints consistent with tuberculosis.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled TrialMycobacterium Avium-intracellulare InfectionHIV InfectionsNCT00002267Pharmacia750
已完成
不适用
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled TrialMycobacterium Avium-intracellulare InfectionHIV InfectionsNCT00002032Pharmacia750
已完成
不适用
A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDSMycobacterium Avium-Intracellulare InfectionHIV InfectionsNCT00001995Pharmacia200
Unknown
不适用
Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)Silicosis TuberculosisNCT03900858Huashan Hospital566
进行中（未招募）
不适用
Preventive therapy for multidrug-resistant tuberculosis: a multicentre clincal trial. - MOXEPEUCTR2008-006765-82-ITISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI